Table 2.
Phase 2 and Phase 3 Clinical Trials Evaluating Elotuzumab in High-Risk or R/R Multiple Myeloma.
| Study NCT# | Reference URL | Study title | Phase of Trial |
|---|---|---|---|
| NCT02718833 | https://ClinicalTrials.gov/show/NCT02718833 | A Phase 2 Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma | 2 |
| NCT03155100 | https://ClinicalTrials.gov/show/NCT03155100 | Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1–3 Prior Treatment Lines | 2 |
| NCT03030261 | https://ClinicalTrials.gov/show/NCT03030261 | A Phase 2 Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma | 2 |
| NCT02654132 | https://ClinicalTrials.gov/show/NCT02654132 | An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | 2 |
| NCT02612779 | https://ClinicalTrials.gov/show/NCT02612779 | A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | 2 |
| NCT03361306 | https://ClinicalTrials.gov/show/NCT03361306 | LCI-HEM-MYE-CRD-002: A Phase 2 Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | 2 |
| NCT02843074 | https://ClinicalTrials.gov/show/NCT02843074 | Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma | 2 |
| NCT03411031 | https://ClinicalTrials.gov/show/NCT03411031 | A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma | 2 |
| NCT01891643 | https://ClinicalTrials.gov/show/NCT01891643 | A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma | 3 |
| NCT03104270 | https://ClinicalTrials.gov/show/NCT03104270 | A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/Refractory Multiple Myeloma Patients | 2 |
| NCT02420860 | https://ClinicalTrials.gov/show/NCT02420860 | Phase 2 Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma | 2 |
| NCT02495922 | https://ClinicalTrials.gov/show/NCT02495922 | A Randomized Phase 3 Trial on the Effect of Elotuzumab in VRD Induction/Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | 3 |
| NCT02726581 | https://ClinicalTrials.gov/show/NCT02726581 | An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma | 3 |